#USA #San Diego #RNA Therapeutics #Avidity Biosciences #Nasdaq Grants

Avidity Biosciences Inducement Grants: Attracting New Talent

Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneering biopharmaceutical firm, has taken a major step to enhance its workforce. On February 20, 2025, the company unveiled a substantial grant of stock options and restricted stock units (RSUs) for new employees as part of its strategy to recruit top talent. This move is aligned with Nasdaq's Listing Rule 5635(c)(4), which facilitates inducement grants as a means to attract individuals who are not current employees of the company.

Overview of the Inducement Grants

The grants announced by Avidity include non-qualified stock options allowing the purchase of a total of 107,000 shares along with 53,500 RSUs. These were allocated to twenty-two new non-executive personnel joining Avidity. The equity awards are designed to extend Avidity's appeal in a competitive biopharmaceutical landscape, particularly in the innovative field of RNA therapeutics where they focus on Antibody Oligonucleotide Conjugates (AOCs™).

Details of the Stock Options and RSUs

The stock options feature an exercise price set at $32.53 per share, matching Avidity's closing stock price on The Nasdaq Global Market on the grant date. Vested over a four-year period, these stock options ensure that 25% of the shares will become available one year after the grant, with the remainder unlocking in equal monthly installments over the subsequent three years, contingent upon continued employment with the company.

For the RSUs, they will vest in four equal portions on the anniversaries of the commencement date, again reliant on the employee's ongoing affiliation with Avidity. This structured approach to vesting underscores Avidity's commitment to fostering employee retention while simultaneously rewarding individuals for their contributions over time.

Avidity's Mission and Innovative Approach

Avidity Biosciences is on a mission to revolutionize the treatment of diseases previously deemed unreachable through traditional RNA therapies. Their proprietary AOC platform leads the charge in this endeavor, enabling targeted delivery of RNA therapeutics directly to affected muscle tissues. They are particularly noted for their clinical development programs aimed at addressing rare neuromuscular disorders such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.

Moreover, the company is expanding its pipeline with precision cardiology candidates aimed at tackling genetic cardiomyopathies, demonstrating its versatility and broadening scope of research and development. By nurturing partnerships and exploring new frontiers in immunology and cardiology, Avidity seeks to enhance the potential of its AOC platform further.

Conclusion

The recent inducement grants signal Avidity Biosciences' proactive measures to secure top-tier talent in the biopharmaceutical sector. By integrating competitive equity awards into their employment strategies, Avidity is not only positioning itself as a frontrunner in RNA therapeutics but also laying a robust foundation for future growth and innovation. As the company moves forward, its efforts to foster a dedicated workforce will be crucial for maintaining momentum in their ambitious objectives. For those interested in learning more, further details are available on Avidity's official website.

For additional inquiries, you can contact:

• - Investor Contact: Kat Lange (619) 837-5014
• - Media Contact (619) 837-5016

By positioning itself strategically in the competitive landscape of biopharmaceuticals through such grants, Avidity is undoubtedly setting the stage for a new era of growth and potential breakthroughs in treatment methodologies.